The history of Sildenafil presents a complex case for stakeholders in the medicinal sector. While initially a phenomenal success, creating huge profits, the intellectual property lapse and the subsequent entry of cheaper versions have significantly changed earnings. This raises questions about the future viability of similar drug innovations and su